Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Tal R, Motro M, Vered ZVI and Ezra D (1991)
Ozempic (semaglutide) Originally developed for diabetes, its also used off-label for weight loss under expert supervision
As one of the fastest-growing pharmaceutical markets, GLP-1 therapies are forecasted to exceed $100 billion by 2030
Patients with specific predispositions may experience faster weight loss, fewer side effects, or greater appetite suppression on tirzepatide compared to semaglutide
Compared to Ozempic and Mounjaro, Trulicity produces more modest A1C reductions and weight loss patients who need stronger glycemic control or greater weight reduction may be better served by those alternatives with their prescriber's guidance
9.4 Interaction with Weight Loss Medications Concurrent use with other weight loss agents requires caution due to additive effects